Zobrazeno 11 - 20
of 39
pro vyhledávání: '"Georgi, Shukarev"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 2, Pp 266-270 (2017)
The consequences of the 2013–16 Ebola Zaire virus disease epidemic in West Africa were grave. The economies, healthcare systems and communities of Guinea, Sierra Leone and Liberia were devastated by over 18 months of active Ebola virus transmission
Externí odkaz:
https://doaj.org/article/40c64edefea643de830eb816994756fa
Autor:
Jerald, Sadoff, Glenda, Gray, An, Vandebosch, Vicky, Cárdenas, Georgi, Shukarev, Beatriz, Grinsztejn, Paul A, Goepfert, Carla, Truyers, Hein, Fennema, Bart, Spiessens, Kim, Offergeld, Gert, Scheper, Kimberly L, Taylor, Merlin L, Robb, John, Treanor, Dan H, Barouch, Jeffrey, Stoddard, Martin F, Ryser, Mary A, Marovich, Kathleen M, Neuzil, Lawrence, Corey, Nancy, Cauwenberghs, Tamzin, Tanner, Karin, Hardt, Javier, Ruiz-Guiñazú, Mathieu, Le Gars, Hanneke, Schuitemaker, Johan, Van Hoof, Frank, Struyf, Macaya, Douoguih, Marcus, Zervos
Publikováno v:
New England Journal of Medicine. 384:2187-2201
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.In an internation
Autor:
Hester van Zeeburg, Conor Cahill, Jeanne-Marie Jacquet, Richard de Rooij, Martin Struijs, Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
HUMAN VACCINES & IMMUNOTHERAPEUTICS
article-version (VoR) Version of Record
HUMAN VACCINES & IMMUNOTHERAPEUTICS
This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6 (R) cell line. Healthy adults (N = 32) were randomized (1:
Autor:
Jerald, Sadoff, Glenda, Gray, An, Vandebosch, Vicky, Cárdenas, Georgi, Shukarev, Beatriz, Grinsztejn, Paul A, Goepfert, Carla, Truyers, Ilse, Van Dromme, Bart, Spiessens, Johan, Vingerhoets, Jerome, Custers, Gert, Scheper, Merlin L, Robb, John, Treanor, Martin F, Ryser, Dan H, Barouch, Edith, Swann, Mary A, Marovich, Kathleen M, Neuzil, Lawrence, Corey, Jeffrey, Stoddard, Karin, Hardt, Javier, Ruiz-Guiñazú, Mathieu, Le Gars, Hanneke, Schuitemaker, Johan, Van Hoof, Frank, Struyf, Macaya, Douoguih, Marcus, Zervos
Publikováno v:
The New England journal of medicine. 386(9)
The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.We conducted the final analysis in the double-blind phase of our multination
Autor:
Jerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Mandy Jongeneelen, Krisztian Kaszas, Jeroen Tolboom, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Publikováno v:
Vaccine. 40(32)
Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting.In randomized, double-blind, placebo-controlled, phase 1/2a a
Autor:
Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, Dickson Anumenden, Jeroen N. Stoop, Anne Marit de Groot, Maria G. Pau, Jenny Hendriks, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Publikováno v:
PloS one. 17(10)
Background Though clinically similar, Ebola virus disease and Marburg virus disease are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major outbreaks (≥200 cases; five caused by Zair
Autor:
Georgi Shukarev, Helen R Wagstaffe, Jeroen N Stoop, Viki Bockstal, Eleanor M. Riley, Kerstin Luhn, Matthew D. Snape, Andrew J. Pollard, Martin R. Goodier, Macaya Douoguih, Elizabeth A. Clutterbuck
Publikováno v:
The Journal of Infectious Diseases
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Background Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent
Autor:
Jerald C. Sadoff, Macaya Douoguih, Frank Struyf, Gert Scheper, M. Juliana McElrath, Hanneke Schuitemaker, Carla Truyers, Georgi Shukarev, Stephen C. De Rosa, Mathieu Le Gars, Kristen W. Cohen, Jenny Hendriks, Dirk Heerwegh
Publikováno v:
Respiratory infections and bronchiectasis.
Autor:
Hilary S. Whitworth, Pontiano Kaleebu, George PrayGod, Macaya Douoguih, Saidi Kapiga, Deborah Watson-Jones, Dickson Anumendem, Kerstin Luhn, Samuel E. Kalluvya, Cynthia Robinson, Georgi Shukarev, Daniela Manno, Viki Bockstal, Zacchaeus Anywaine, Heiner Grosskurth
Publikováno v:
The Journal of Infectious Diseases
Background Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccina
Autor:
Mathieu Le Gars, Jerald Sadoff, Mandy Jongeneelen, Dirk Heerwegh, Georgi Shukarev, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Boerries Brandenburg, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Publikováno v:
Open Forum Infectious Diseases
Background In a Phase 3 trial, the Janssen COVID-19 vaccine, Ad26.COV2.S, showed robust efficacy against severe–critical COVID-19 in countries where different SARS-CoV-2 variants were circulating. We evaluated Ad26.COV2.S-elicited antibody neutrali